Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Single-arm, Phase Ib Study of the Efficacy and Safety of IBI310 Combined with Sintilimab in Patients with Advanced Hepatocellular Carcinoma

NCT04401813 is registered in ClinicalTrials.gov with Innovent Biologics (Suzhou) Co. Ltd. as lead sponsor.

NCT NCT04401813
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04401813 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Single-arm, Phase Ib Study of the Efficacy and Safety of IBI310 Combined with Sintilimab in Patients with Advanced Hepatocellular Carcinoma
Lead sponsor
Innovent Biologics (Suzhou) Co. Ltd.
Phase
Phase 1
Overall status
Completed
Start date
June 16, 2020
Completion date
June 21, 2024
Enrollment
97 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced hepatocellular carcinoma